The treatment of low-tumour burden follicular lymphoma (LTBFL) remains a challenge. Rituximab-based strategies may be improved by adding chemotherapy. This Lymphoma Study Association multicentre phase II study assessed rituximab and bendamustine in 63 patients with untreated LTBFL who were aged over 60 years old and had a follicular lymphoma International Prognostic Index (FLIPI) score ≥2. Induction comprised 4 weekly cycles of rituximab 375 mg/m 2 intravenously combined with 2 cycles of bendamustine 90 mg/m 2 days 1-2 with a 28-day interval, followed by twelve cycles of 375 mg/m 2 rituximab maintenance therapy every 8 weeks. The primary endpoint was complete response (CR)/unconfirmed CR (CRu), at 12 weeks. Median age was 67Á4 years and median FLIPI was 3. Ultimately, 18 patients (29%) had high tumour burden according to Groupe d'Etude des Lymphomes Folliculaires criteria. The 12-week CR/ CRu rate was 54Á0% and the overall response rate was 93Á7%. Surprisingly, 3 patients died during maintenance (2 sepsis, 1 neoplasm). Progression-free survival was 85Á4% at 24 months. In LTBFL patients with FLIPI ≥2, two cycles of rituximab and bendamustine result in a CR rate of 54Á0%. However, the treatment-related deaths observed do not allow this regimen to be recommended for LTBFL patients aged over 60 years.
Asymptomatic low-tumour burden follicular lymphoma (LTBFL) is a presentation of follicular lymphoma (FL) without high-tumour burden (HTB) criteria according to Groupe d'Etude des Lymphomes Folliculaires (GELF; Brice et al, 1997; Solal-C eligny et al, 1998) or British National Lymphoma Investigation (Ardeshna et al, 2003) criteria. A watch-and-wait (WW) strategy is acceptable in LTBFL (Horning & Rosenberg, 1984) , as no overall survival (OS) benefit has been observed with immediate treatment in randomised studies (Brice et al, 1997; Ardeshna et al, 2003) .
Four weekly courses of rituximab (4R) as monotherapy result in an overall response rate (ORR) of 80% with a complete response [CR: CR+unconfirmed CR (CRu)] rate (Cheson et al, 1999 ) of 52% and a median progression-free survival (PFS) of 23Á4 months (Colombat et al, 2001 (Colombat et al, , 2012 . A longer time to next treatment has been observed with 4R compared to WW [hazard ratio (HR) = 0Á21; P < 0Á0001] without OS benefit (Ardeshna et al, 2014) . In LTBFL, maintenance therapy with rituximab has also been associated with a longer time to start of new treatment (TTNT) (HR = 0Á53; P = 0Á011) (Ardeshna et al, 2014) , without OS benefit. However, some patients with LTBFL may have unfavourable prognostic factors at diagnosis, such as a high FL International Prognostic Index (FLIPI) score (Solal-C eligny et al, 2004) , and require a shorter time to treatment initiation (Solal-C eligny et al, 2012) . In a study assessing LTBFL patients treated with 4R with a follow-up of more than 7 years, no patient with a high FLIPI score achieved a longterm remission (Colombat et al, 2006) . In the RESORT study comparing maintenance therapy with rituximab to re-treatment with 4R in LTBFL, CR was only 11Á8% after 4R induction, mostly because of missing bone marrow evaluation . This study did not show an improvement in TTNT with planned maintenance compared with rituximab monotherapy at time of progression. However, an intermediate or high FLIPI score was associated with an increased risk of progression in multivariable analysis [HR = 1Á71; 95% confidence interval, CI (1Á01-2Á87)] . These LTBFL patients with a high FLIPI score might benefit from a more intensive approach.
Bendamustine has been assessed in FL in combination with rituximab. In a phase II study in patients with relapsed/ refractory low-grade lymphomas, 4 cycles of bendamustine and rituximab (BR) resulted in a CR rate of 60% with a median PFS of 24 months (Rummel et al, 2005) . Two prospective randomised studies comparing BR to R-chemotherapy (mostly R-CHOP: rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) as first-line therapy have shown CR rates of 40% and 31%, and 93% and 97% in the StiL (Rummel et al, 2013) and BRIGHT studies, respectively. In the StiL study, FL patients showed a prolonged PFS compared to that achieved with R-CHOP (HR = 0Á61, P = 0Á072), while the toxicity of BR appeared lower. To our knowledge, BR has not yet been assessed in LTBFL.
The aim of the multicentric phase II BRIEF study was to assess the efficacy and toxicity of 2 cycles of BR followed by maintenance therapy in untreated LTBFL patients with a FLIPI score of 2 or above.
Patients and methods

Eligibility
Inclusion criteria were: histologically confirmed CD20 + FL (grades 1, 2 and 3a), age ≥60 years, untreated FL, Eastern Cooperative Oncology Group (ECOG) performance score between 0 and 2, adequate haematological function (unless related to lymphoma), adequate renal, cardiac and hepatic functions, low tumour burden (GELF criteria) with intermediate or high FLIPI score; at least one measurable lesion. Low tumour burden was defined as: no mass >7 cm, less than three masses >3 cm, no systemic or B symptoms, no splenic enlargement, no compressive syndrome, no increased lactate dehydrogenase (LDH) or b 2 -microglobulin levels, and no cytopenia (defined as platelet count <100 9 10 9 /l, haemoglobin <100 g/l or absolute neutrophil count <1Á5 9 10 9 / l,). Patients were excluded if they were positive for human immunodeficiency virus, hepatitis B core (HBc) antigens or hepatitis C virus, or if they had any prior or concomitant malignancies. 
Efficacy assessments
Response was assessed using the 1999 (Cheson et al, 1999) and 2007 (Cheson et al, 2007) International Working Group (IWG) criteria after the induction phase, at week 12. Final assessment was made at week 108 (Fig 1) .
Statistics
The primary endpoint was the CR rate according to 1999 IWG criteria (Cheson et al, 1999) after induction treatment.
Secondary endpoints were the CR rate according to 2007 IWG criteria (Cheson et al, 2007) 
Data analysis
Efficacy was assessed in all patients included in the study. Safety was assessed in patients who received at least one dose of experimental drug (i.e., rituximab or bendamustine). The per-protocol analysis was performed in patients who met all inclusion and exclusion criteria.
Ethics
The BRIEF protocol was approved by the ethics committee of Nancy, France, on December 23, 2010 and by the National Agency for Medicines and Health Products Safety (ANSM) on December 10, 2010. The study was conducted in accordance with the declaration of Helsinki. Patients were asked to provide written informed consent before registration.
Results
Patient distribution
Sixty-three patients were included in the study between 22 any study drug (inclusion criteria violation) and was excluded from the toxicity analysis. One patient experienced grade 1 diarrhoea and fever during the induction phase, precluding the administration of bendamustine at day 30, but was included in the toxicity and efficacy analyses (Fig 2) .
Pathology review
After pathology review, all diagnoses of FL were confirmed, except for 1 patient whose tumour was classified as diffuse large B cell lymphoma (DLBCL) and 1 patient with grade 3B FL. Histological samples of six patients could not be reviewed because no additional material was available (Table I ).
Patient characteristics
The 63 patients included 34 men and 29 women, with a median age of 67Á4 years (range: 61-84). The median Cumulative Illness Rating Scale-Geriatric (CIRS-G) score was of 3 (range: 0-10) and most patients (76Á2%) had an ECOG performance score equal to 0. All patients but one had a stage III-IV disease and most of them had a high FLIPI score (69Á8%). Lymphoma involvement was nodal in all cases (100%), and 42 (66Á7%) patients also had extranodal disease. Characteristics are detailed in Table I .
Compliance
Unexpectedly, deviations from the inclusion/exclusion criteria were observed in 25 patients (39Á6%), with the presence of 1 or more GELF high tumour burden (HTB) criteria in 18 patients (tumour >7 cm: 8; B symptoms: 5; high LDH level: 4; high b 2 -microglobulin level: 6; 3 sites larger than 3 cm: 5; symptomatic splenomegaly: 3; compressive symptoms: 5; serous effusion: 1), diagnosis made more than 6 months ago (2 patients), 1 DLBCL and 1 grade 3B FL (after pathology review). The median percentage of planned dose received during the induction phase was 99Á1% (quartile [Q]1-Q3: 98-100) for bendamustine and 98Á9% (Q1-Q3: 98-100) for rituximab. As soon as the decision to discontinue the maintenance therapy with rituximab was made by the Data and Safety monitoring committee (DSMC) due to three lethal therapy-related cases observed, all patients immediately discontinued treatment.
Response at the end of induction
According to 1999 IWG criteria (Cheson et al, 1999) , 34 out of the 63 [54Á0%; 95% CI (40Á9-66Á6)] patients achieved a CR/ CRu at the end of the induction phase. The ORR was 93Á7% [95% CI (85Á8-99Á9)]. According to 2007 IWG criteria (Cheson et al, 2007 , the CR rate was 57Á1% and the ORR was Study flowchart. Sixty-three patients were included in the study and efficacy analysis. One patient did not receive study treatment because of inclusion criteria violation and was excluded from the safety analysis. The other reasons for treatment discontinuation are indicated in the boxes on the right. B, bendamustine. Asterisks (*) indicate the deaths that occured during the study. 95Á2%, respectively. Ten patients with a negative 18 FDG-PETscan were considered in PR only because a BM assessment was missing (Fig 3) . In the 37 patients of the per protocol population, the CR rate was 59Á4% and the ORR was 91Á9%. Among the 18 patients retrospectively assessed as HTB and the 43 LTB patients (2 missing data), CR was achieved in 9 (50Á0%) and 23 (53Á5%), respectively (P = 1Á0), while ORR was achieved in 18 (100%) and 39 (90Á7%), respectively. No pretherapeutic criteria were found to predict a CR.
At the end of treatment (including maintenance phase for responders), 48 (76Á2%) and 57 (90Á5%) patients achieved a CR/CRu and OR, respectively, according to 1999 IWG criteria, whereas 42 (66Á7%) and 46 (73%) patients achieved a CR and OR according to 2007 IWG criteria, respectively.
Tolerance
Most AEs were haematological and leucopenia occurred in more than half of the patients (Table II) . All observed toxicities are detailed in Fig 4. Thirteen patients experienced 37 SAEs during the study, one patient before and 2 patients during the induction phase, 10 during the maintenance phase and 2 during the follow-up. The first pre-planned DSMC met on 10 July 2012. During this meeting, two deaths were carefully examined and were considered as possibly related to study treatments (one infection and one adenocarcinoma). When a third death (infection), occurring 6 months after study entry, was reported to the pharmacovigilance department, the DSMC was contacted and immediately recommended (October 2012) to discontinue treatment with rituximab during the maintenance phase, which resulted in early study termination for 56 patients (Fig 2) , and additional safety monitoring recommendations in which CD4/ CD8, serum electrophoresis and IgA, IgG and IgM assessments were added to the follow-up. The characteristics of the 3 patients with a fatal outcome are presented in Table III .
Progression
Survival was studied until 1 July 2016, after a median follow-up of 52 months. A total of 13 (20Á6%) patients experienced 
Survival
Median OS was not reached with the 3 previously mentioned deaths unrelated to lymphoma, and 1 related to lymphoma progression lymphoma, Fig 5B) . No further analysis could be performed due to the limited number of events.
Discussion
The results of the BRIEF study indicate that two cycles of BR result in a CR/CRu rate of 54Á0% and an ORR of 95Á2% according to 1999 IWG criteria (Cheson et al, 1999) in treatment-na€ ıve LTBFL patients with a FLIPI score greater than or equal to 2. One originality of our study is the definition of the population (i.e. low tumour burden with intermediate-to-high FLIPI score), which had not been evaluated in other studies. Median PFS and OS were not reached with the actual follow-up. Our observed PFS (85Á4% at 24 months) is higher than that observed with 4 weekly courses of rituximab (4R) in most studies.
In the phase II study assessing 4R in treatment-naive LTBFL patients, the best CR rate (at any time during 1 year after treatment) was 52%, the ORR was 80%, and the median PFS was 23Á5 months (Colombat et al, 2001 (Colombat et al, , 2012 , and these values are lower than in our study. Similarly, in a phase II study assessing 4R in asymptomatic newly diagnosed advanced FL patients from the North Central Cancer Treatment Group, the CR rate was 36%, the ORR 72% and the median time to progression (TTP) 2Á2 years. Interestingly, patients with high LDH had a lower ORR (33%) and a shorter TTP (6 months) (Witzig et al, 2005) . The RESORT study has also assessed 4R retreatment at the time of LTBFL progression in patients initially treated with 4R, compared to maintenance therapy with rituximab. The CR rate after the induction phase was 11Á8%, the ORR was 70Á8%, and the time to treatment failure was not different, at 61% and 64% at 3 years in the retreatment and maintenance arms, respectively . However, the GELF criteria used in this study did not take into account high LDH or b 2 -microglobulin levels, which were found in 13% and 42% of patients, respectively. In the 'rituximab versus watch-andwait' (RWW) study, the CR rate at 7 months was 36%, the ORR was 77% and the median PFS was longer than 4 years in the 4R induction arm, and increased to 51%, 88% and not reached, respectively in the 4R + R maintenance arm (Ardeshna et al, 2014) . Our efficacy results compare favourably with these studies.
Toxicities were mostly haematological and manageable for most patients, with no significant grade 3/4 toxicity. However, we unexpectedly observed 3 deaths related to treatment. Therefore, the DSMB decided to discontinue study treatment administration. Treatment-related deaths have not been reported in the two previously published rituximab and bendamustine studies (Rummel et al, 2013; Flinn et al, 2014) . The reasons for these unanticipated toxicities are unclear. One patient who died from Streptococcus pneumoniae lung infection had profound hypogammaglobulinaemia (Table III) , whereas the two others had no risk factors. In this context, the possibility that an intensive treatment with 4 doses of rituximab over the first month of the induction phase could increase immunosuppression cannot be completely ruled out. The fact that no mandatory antimicrobial prophylaxis or growth factor use was planned may have also contributed to some degree of vulnerability.
Of note, in the recently reported GALLIUM study, it appeared in preliminary results that a small excess of severe and eventually fatal toxicities occurred predominantly during the bi-monthly R maintenance period in patients receiving BR as compared to rituximab and CVP (cyclophosphamide, vincristine, and prednisone) or CHOP as induction therapy (although this was not a randomized comparison) (Marcus et al, 2016) . On the other hand, the recent US phase 3 HTB FL study report of the comparison of BR to bortezomib+BR, and of evaluation of the addition of lenalidomide to R maintenance did not find treatment-related mortality to be an issue (Evens et al, 2017) .
The 18 FDG-PET-scan, performed to monitor the response, also showed that the metabolic response was higher than in the 2007 IWG definition of the CR because some BM biopsies were missing, indicating that 2 cycles of BR could lead to 91Á8% PET-scan negativity. The impact of missing BM biopsies on the calculation of the CR according to 1999 IWG criteria has not been assessed, to our knowledge, in other FL studies.
A concern of our study is that some patients with HTB characteristics were included in the trial. This could be due to the unusual inclusion criteria associating the FLIPI score and GELF criteria. However, regarding the per protocol population, the fact that most relapses occurred in sites initially involved suggests that 2 cycles of BR, even if followed by some rituximab maintenance cycles, could not reduce FL minimal residual disease enough to allow a prolonged remission.
Non-chemotherapeutic approaches, such as rituximab and lenalidomide combinations , alternative anti-CD20 monoclonal antibodies (Negrea et al, 2011; (Roberts et al, 2015) , HDAC inhbitors (Chen et al, 2015) , PI3 kinase inhibitors (Gopal et al, 2014) , immunomodulatory drugs Leonard et al, 2015) , immunotherapies , or proteasome inhibitors (Evens et al, 2014) , with or without rituximab, are promising. The role of rituximab maintenance therapy in LTBFL is unclear, with evidence from the RESORT trial indicating that maintenance treatment might be dispensable .
Based on our findings, we do not recommend the BRIEF schedule of rituximab and bendamustine followed by rituximab maintenance therapy for low-burden FL, even when the FLIPI score is greater than or equal to 2. The monitoring of patients for prolonged lymphopenia and/or low CD4 + T cells, as well as the implementation of a mandatory antimicrobial prophylaxis, such as cotrimoxazole and valaciclovir, and appropriate immunoglobulin support should be considered for such a combination, which will need to be validated in a prospective randomized study. The wealth in novel non-chemotherapeutic agents may also provide attractive alternatives for the management of untreated lowtumour burden FL with unfavourable prognostic factors. 
OS from inclusion -FAS
With number of subjects at risk In conclusion, two cycles of bendamustine administered concomitantly with 4 weekly cycles of rituximab may result in a high response rate and PFS. Due to the observed toxicity-related deaths, this regimen may not be recommended in LTBFL. Further research to identify short-term treatments with low toxicity and prolonged PFS should be encouraged for these patients. Authorship E.G., A.S, and P.F. designed the study, wrote the protocol, recruited patients, collected data, analysed data and wrote the manuscript. P.B., B.A., K.L., C.F., H.T., C.A., P.S., H.G., N.M., E.N.-V., H.G., B.S., R.B., H.O., and J.F. approved the protocol, included patients, collected data and revised the manuscript. L.X. performed pathology review. O.C. performed the imaging review. All authors approved the final version of the manuscript.
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